通过RACK7基因组脱甲基酶复合物抑制增强剂过度激活
Hongjie Shen1, Wenqi Xu1, Rui Guo2
1Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, and Key Laboratory of Epigenetics, Department of Cellular and Genetic Medicine, School of Basic Medical Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Key Laboratory of Birth Defect, Children's Hospital of Fudan University, Shanghai 201102, China.
RACK7/KDM5C复合体作为增强制动剂,控制基因表达. 它的损失导致增强剂过度激活,并通过抑制瘤基因促进癌症的发展.
科学领域:
- 生物化学
- 分子生物学
- 表观遗传学
背景情况:
- 基因表达受到增强剂活性的严格调节.
- 了解控制增强剂的机制对于解读基因调节和疾病发展至关重要.
研究的目的:
- 调查RACK7/KDM5C复合体在调节增强剂活性中的作用.
- 阐明RACK7/KDM5C控制基因表达及其在癌症中的影响的分子机制.
主要方法:
- 生物化学复杂的分离和表征.
- 染色体免疫沉测序 (ChIP-seq) 用于分析基因组修饰 (H3K4me3,H3K4me1,H3K27Ac).
- 定量实时PCR (qRT-PCR) 用于ERNA和基因表达分析.
- 与癌症相关的表型分析.
主要成果:
- 在活性增强剂中发现RACK7/KDM5C复合物,包括超级增强剂.
- RACK7或KDM5C的丧失导致增强剂过度激活,其特征是H3K4me3和H3K27Ac的增加.
- 破坏RACK7/KDM5C导致eRNA和附近基因转录的增加.
- 减少RACK7/KDM5C导致S100A瘤基因的抑制,并促进癌症表型.
结论:
- RACK7/KDM5C作为增强车,调节H3K4me1和H3K4me3之间的动态交换.
- 受损的RACK7/KDM5C功能通过异常增强剂活性和瘤基因抑制导致瘤发生.
更多相关视频
10:28Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
相关概念视频
Spreading of Chromatin Modifications
Writers
The writer...
Co-activators and Co-repressors
Co-activators and Co-repressors
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Histone Modification
RNA Polymerase II Accessory Proteins
